Brentuximab vedotin
Also known as: Adcetris, Brentuximab vedotin, cAC10-vcMMAE, SGN-35
Source Brentuximab vedotin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Brentuximab vedotin (Adcetris) is an FDA‑approved CD30‑targeted antibody‑drug conjugate indicated for Hodgkin lymphoma and systemic anaplastic large‑cell lymphoma.
Mechanism of Action
CD30-directed monoclonal antibody delivers MMAE intracellularly, inhibiting microtubule polymerization and inducing apoptosis of CD30+ malignant cells
Routes of Administration
Goals & Uses
- Classical Hodgkin lymphoma (relapsed/refractory)OncologyHigh
- Primary cutaneous ALCL or CD30-expressing mycosis fungoidesOncologyHigh
- Systemic ALCLOncologyHigh
- Systemic anaplastic large cell lymphoma (relapsed/refractory)OncologyHigh
- Previously untreated Stage III/IV cHL (with AVD)OncologyHigh
- Post-ASCT consolidation in cHL at high risk of relapseOncologyHigh
- Previously untreated CD30+ peripheral T-cell lymphomaOncologyHigh
- Hodgkin lymphomaOncologyHigh
Contraindications
- Known severe hypersensitivity to brentuximab vedotinHypersensitivityHigh
- Concurrent bleomycin useDrug CombinationHigh
- Known hypersensitivity to brentuximab vedotin or any componentAllergyHigh
- Progressive multifocal leukoencephalopathy (PML) riskNeurologicalHigh
Adverse Effects
- Peripheral neuropathyNeurologicalCommon
- Infusion‑related reactionsGeneralUncommon
- Progressive multifocal leukoencephalopathy (PML)NeurologicalRare
- Nausea and vomitingGastrointestinalCommon
- NeutropeniaHematologicCommonLow neutrophil count
- FatigueGeneralCommonLow energy or tiredness
- Peripheral sensory neuropathyNeurologicalCommon
- FeverSystemicCommonElevated body temperature
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- BleomycinHigh
- Strong CYP3A4 inducers (e.g., rifampin)Moderate
- Strong CYP3A4 inhibitors (e.g., ketoconazole)Moderate
- P-glycoprotein inhibitorsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairment (moderate to severe)Organ ImpairmentRelative
- Pediatric patientsAgeRelative
- Severe renal impairment (CrCl <30 mL/min)Organ ImpairmentRelative
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Hodgkin lymphoma, Systemic anaplastic large‑cell lymphomaEMA approval 2012
- United StatesApprovedApproved: Hodgkin lymphoma, Systemic anaplastic large‑cell lymphomaFDA approval 2011
- United KingdomApprovedApproved: Hodgkin lymphoma, Systemic anaplastic large‑cell lymphomaMHRA approval
Approved by FDA (2011) and EMA; marketed under the brand Adcetris; contains monomethyl auristatin E linked via a protease‑cleavable valine‑citrulline linker.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Brentuximab vedotin?
Brentuximab vedotin (Adcetris) is an FDA‑approved CD30‑targeted antibody‑drug conjugate indicated for Hodgkin lymphoma and systemic anaplastic large‑cell lymphoma.
What is Brentuximab vedotin used for?
Brentuximab vedotin is educationally associated with: Classical Hodgkin lymphoma (relapsed/refractory), Primary cutaneous ALCL or CD30-expressing mycosis fungoides, Systemic ALCL, Systemic anaplastic large cell lymphoma (relapsed/refractory), Previously untreated Stage III/IV cHL (with AVD), Post-ASCT consolidation in cHL at high risk of relapse, Previously untreated CD30+ peripheral T-cell lymphoma, Hodgkin lymphoma. Educational only — not medical advice.
How is Brentuximab vedotin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Brentuximab vedotin?
Reported adverse effects include: Peripheral neuropathy, Infusion‑related reactions, Progressive multifocal leukoencephalopathy (PML), Nausea and vomiting, Neutropenia, Fatigue, Peripheral sensory neuropathy, Fever, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Brentuximab vedotin?
Recorded contraindications: Known severe hypersensitivity to brentuximab vedotin, Concurrent bleomycin use, Known hypersensitivity to brentuximab vedotin or any component, Progressive multifocal leukoencephalopathy (PML) risk. Consult a qualified clinician before use.